Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE GLYCOL 6000

Branded drugs containing POLYETHYLENE GLYCOL 6000 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	BONIVA	ibandronate sodium	0004-0186	POLYETHYLENE GLYCOL 6000
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	POLYETHYLENE GLYCOL 6000
Sanofi-Aventis US LLC	PLAVIX	clopidogrel	0024-1171	POLYETHYLENE GLYCOL 6000
Sanofi-Aventis US LLC	MULTAQ	dronedarone	0024-4142	POLYETHYLENE GLYCOL 6000
UCB Inc	UNIVASC	moexipril hydrochloride	0091-3707	POLYETHYLENE GLYCOL 6000
AstraZeneca Pharmaceuticals LP	TOPROL	metoprolol succinate	0186-1088	POLYETHYLENE GLYCOL 6000

Generic drugs containing POLYETHYLENE GLYCOL 6000 excipient

Company	Ingredient	NDC	Excipient
Genentech Inc	ibandronate sodium	0004-0186	POLYETHYLENE GLYCOL 6000
Pharmacia & Upjohn Company LLC	exemestane	0009-7663	POLYETHYLENE GLYCOL 6000
Sanofi-Aventis US LLC	clopidogrel	0024-1171	POLYETHYLENE GLYCOL 6000
Sanofi-Aventis US LLC	dronedarone	0024-4142	POLYETHYLENE GLYCOL 6000
UCB Inc	moexipril hydrochloride	0091-3707	POLYETHYLENE GLYCOL 6000
Teva Pharmaceuticals USA, Inc.	tolterodine tartrate	0093-0010	POLYETHYLENE GLYCOL 6000

Market Dynamics and Financial Trajectory for Polyethylene Glycol 6000

Last updated: February 20, 2026

Polyethylene glycol 6000 (PEG 6000) is a non-ionic, water-soluble polymer used widely in pharmaceutical formulations, food products, cosmetics, and industrial applications. Its market valuation has experienced steady growth driven by expanding pharmaceutical and biotech sectors.

Market Overview

The PEG 6000 market was valued at approximately USD 250 million in 2022. Projected Compound Annual Growth Rate (CAGR) is around 6% from 2023 to 2030. The demand stems primarily from pharmaceutical manufacturing, where PEG 6000 functions as a laxative, binder, and solubilizer.

Key Market Drivers

• Pharmaceutical Growth: Increased demand for solid dosage forms and controlled-release formulations. PEG 6000 enhances drug bioavailability and stability.
• Biopharmaceutical Applications: Usage as a carrier in bioconjugation and drug delivery systems.
• Cosmetics & Personal Care: Usage as a thickening agent, humectant, and stabilizer.
• Food Industry: Used in food additives, although less prominent.

Regional Market Breakdown

Region	Market Share (2022)	CAGR (2023-2030)	Growth Drivers
North America	35%	5.5%	Robust pharma sector, R&D investments
Europe	25%	6.0%	Stringent regulations, innovation
Asia-Pacific	30%	6.8%	Growing biotech industries, manufacturing
Rest of World	10%	5.2%	Emerging markets, increasing healthcare expenditure

Competitive Landscape

Major players include:

• BASF SE
• Dow Chemical Company
• DuPont (Chemours)
• Ashland Global Holdings Inc.
• Sinopharm Chemical Reagent Co., Ltd.

Market shares are fragmented with the top five holding nearly 60% combined.

Production and Supply Chain

PEG 6000 production hinges on ethylene oxide polymerization. Capacity is concentrated in North America, Europe, and Asia-Pacific. Supply chain vulnerabilities include raw material price volatility and regulatory compliance challenges.

Financial Projections

Expenditure on research and development impacts profitability margins. Manufacturing scale efficiencies will influence unit costs, with larger-scale producers maintaining competitive pricing.

Year	Estimated Market Size (USD millions)	Key Growth Factors
2023	265	Increased pharma and biotech demand
2025	310	Expansion into emerging markets
2030	350	Product innovation and new application

Challenges and Constraints

• Regulatory hurdles differ globally, adding complexity.
• Raw material costs fluctuate with crude oil prices.
• Environmental concerns over ethylene oxide usage.

Investment Outlook

PEG 6000 is positioned as a stable, moderately growing segment within the excipients market. Strategic investments should target process efficiency, product differentiation, and supply chain resilience.

Key Takeaways

• The PEG 6000 market is valued at USD 250 million (2022), with anticipated growth to USD 350 million by 2030.
• Hydrocarbon-based manufacturing and expanding pharmaceutical applications drive demand.
• Asia-Pacific leads regional growth, with a CAGR of nearly 7%.
• Major players focus on capacity expansion and product innovation.
• Cost, regulation, and environmental factors influence market stability.

FAQs

1. What are the primary uses of PEG 6000 in pharmaceuticals?
PEG 6000 acts as a binder in tablets, a carrier in drug delivery systems, and a solubilizer for poorly soluble drugs.

2. Which regions exhibit the fastest growth for PEG 6000?
Asia-Pacific exhibits the highest CAGR (~6.8%) due to expanding biotech and pharmaceutical sectors.

3. How does regulation impact PEG 6000 supply?
Regulatory requirements for ethylene oxide residues and environmental standards can delay production and increase compliance costs.

4. What are the main raw material risks for PEG 6000 production?
Fluctuating crude oil prices influence ethylene oxide prices, affecting manufacturing costs.

5. How is technological innovation influencing PEG 6000 markets?
Enhanced polymerization techniques and new derivative development improve product performance and open new application avenues.

---

References

1. Grand View Research. (2023). Polyethylene Glycol Market Size, Share & Trends Analysis Report.
2. MarketsandMarkets. (2022). Pharmacology Excipients Market.
3. Applied Markets. (2021). Global PEG Industry Outlook.
4. U.S. Food & Drug Administration. (2022). Regulations for Pharmaceutical Excipients.
5. European Medicines Agency. (2023). Excipients Guidelines.